Role of Monitoring Changes in Sensitive Cardiac Troponin I Assay Results for Early Diagnosis of Myocardial Infarction and Prediction of Risk of Adverse Events
Why the study?
Does monitoring changes (>30% delta) in sensitive cardiac troponin I assay results improve early diagnosis of myocardial infarction and risk prediction in patients with symptoms of ACS?
Population
381 patients presenting with symptoms of acute coronary syndrome (ACS)
Comparison
Measurement of cardiac troponin I using VITROS… vs Baseline or follow-up cTnI concentration alone
Design
Cohort
Follow-up
60 days
Authors
Discussion
Loading...
Member takes
Implication
May aid AMI diagnosis and risk stratification in suspected ACS; hypothesis-generating, requiring prospective validation before practice change.
Structured PICO
Does monitoring changes (>30% delta) in sensitive cardiac troponin I assay results improve early diagnosis of myocardial infarction and risk prediction in patients with symptoms of ACS?
P
Population
381 patients presenting with symptoms of acute coronary syndrome (ACS)
I
Intervention
Measurement of cardiac troponin I (cTnI) using VITROS Troponin I-ES assay on admission and approximately 6 hours postadmission, utilizing a >30% delta
C
Comparator
Baseline or follow-up cTnI concentration alone
O
Outcome
Diagnostic accuracy for acute myocardial infarction (AMI) and risk of cardiac event or death within 60 dayssurrogate
Monitoring changes in sensitive cardiac troponin I (>30% delta) over 6 hours improves the specificity for diagnosing AMI and enhances 60-day risk stratification in patients with suspected ACS.
Cite This Study
Apple et al. (2009) studied this question.